Corona inks agreement with Kitozyme for a fat binder anti-obesity drug

He further added saying, that his company expects obesity patients from non-prescription segment using herbal or ayurvedic drug to shift towards his product - RASVA. According to Mr. Shah, the new product RASVA does not have any side-effect and has ...
See all stories on this topic »

Economic Times

Click for detailed story

Leave a Reply

Your email address will not be published. Required fields are marked *